BRPI0818437A2 - Anticorpo ou fragmento funcional do anticorpo, composição farmacêutica, uso de pelo menosum dos anticorpos ou fragmentos funcionais dos anticorpos, e, hibridoma - Google Patents

Anticorpo ou fragmento funcional do anticorpo, composição farmacêutica, uso de pelo menosum dos anticorpos ou fragmentos funcionais dos anticorpos, e, hibridoma

Info

Publication number: BRPI0818437A2
Authority: BR; Brazil
Prior art keywords: antibodies; antibody; hybridoma; pharmaceutical composition; functional
Prior art date: 2007-10-11

Application number

BRPI0818437-2A

Other languages

English (en)

Inventor

Hioshiharu Hiruma

Eisuke Tsuda

Original Assignee

Dalichi Sankyo Company Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-10-11

Filing date

2008-10-08

Publication date

2015-05-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40549216&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0818437(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-10-08 Application filed by Dalichi Sankyo Company Ltd filed Critical Dalichi Sankyo Company Ltd

2015-05-12 Publication of BRPI0818437A2 publication Critical patent/BRPI0818437A2/pt

2019-01-15 Publication of BRPI0818437A8 publication Critical patent/BRPI0818437A8/pt

2021-03-30 Publication of BRPI0818437B1 publication Critical patent/BRPI0818437B1/pt

2021-05-25 Publication of BRPI0818437B8 publication Critical patent/BRPI0818437B8/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Molecular Biology (AREA)
Rheumatology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Microbiology (AREA)
Biophysics (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Mycology (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Analytical Chemistry (AREA)

BRPI0818437A 2007-10-11 2008-10-08 anticorpo ou fragmento funcional do anticorpo, composição farmacêutica, uso de pelo menos um dos anticorpos ou fragmentos funcionais dos anticorpos, e, hibridoma BRPI0818437B8 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2007-265420		2007-10-11
JP2007265420		2007-10-11
PCT/JP2008/068287 WO2009048072A1 (ja)	2007-10-11	2008-10-08	破骨細胞関連蛋白質Ｓｉｇｌｅｃ－１５を標的とした抗体

Publications (4)

Publication Number	Publication Date
BRPI0818437A2 true BRPI0818437A2 (pt)	2015-05-12
BRPI0818437A8 BRPI0818437A8 (pt)	2019-01-15
BRPI0818437B1 BRPI0818437B1 (pt)	2021-03-30
BRPI0818437B8 BRPI0818437B8 (pt)	2021-05-25

Family

ID=40549216

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0818437A BRPI0818437B8 (pt)	2007-10-11	2008-10-08	anticorpo ou fragmento funcional do anticorpo, composição farmacêutica, uso de pelo menos um dos anticorpos ou fragmentos funcionais dos anticorpos, e, hibridoma

Country Status (24)

Country	Link
US (5)	US8546540B2 (pt)
EP (2)	EP2907826B1 (pt)
JP (4)	JPWO2009048072A1 (pt)
KR (2)	KR101577935B1 (pt)
CN (2)	CN101896501B (pt)
AU (2)	AU2008311698C1 (pt)
BR (1)	BRPI0818437B8 (pt)
CA (2)	CA2875310A1 (pt)
CY (1)	CY1116432T1 (pt)
DK (1)	DK2206727T3 (pt)
ES (2)	ES2540733T3 (pt)
HR (1)	HRP20150485T1 (pt)
HU (1)	HUE025262T2 (pt)
IL (2)	IL204607A (pt)
MX (1)	MX2010003884A (pt)
NZ (1)	NZ583397A (pt)
PL (1)	PL2206727T3 (pt)
PT (1)	PT2206727E (pt)
RU (2)	RU2475499C2 (pt)
SG (2)	SG187523A1 (pt)
SI (1)	SI2206727T1 (pt)
TW (1)	TWI511740B (pt)
WO (1)	WO2009048072A1 (pt)
ZA (1)	ZA201001339B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI359026B (en)	2004-02-12	2012-03-01	Sankyo Co	Pharmaceutical composition for the osteoclast rela
US8168181B2 (en) *	2006-02-13	2012-05-01	Alethia Biotherapeutics, Inc.	Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
CA2822302A1 (en)	2006-02-13	2007-08-23	Alethia Biotherapeutics Inc.	Methods of impairing osteoclast differentiation
RU2475499C2 (ru)	2007-10-11	2013-02-20	Дайити Санкио Компани, Лимитед	Антитело, направленное на белок siglec-15, связанный с остеокластами
NZ605450A (en)	2009-04-09	2014-07-25	Daiichi Sankyo Co Ltd	Anti-siglec-15 antibody
US9114131B2 (en)	2010-10-05	2015-08-25	Daiichi Sankyo Company, Limited	Antibody targeting osteoclast-related protein Siglec-15
JPWO2012050154A1 (ja) *	2010-10-13	2014-02-24	学校法人東京女子医科大学	抗ｖｄａｃ抗体を含有する破骨細胞形成抑制剤
JP6216317B2 (ja) *	2011-09-09	2017-10-18	メディミューンリミテッド	抗Ｓｉｇｌｅｃ−１５抗体およびその使用
RU2014143798A (ru)	2012-03-30	2016-05-27	Дайити Санкио Компани, Лимитед	Антитело к сиглек-15 с модифицированной cdr
US20150125470A1 (en) *	2012-03-30	2015-05-07	Daiichi Sankyo Company, Limited	Novel anti-siglec-15 antibody
CN104507969A (zh)	2012-07-19	2015-04-08	阿莱斯亚生物疗法股份有限公司	抗siglec-15抗体
MX2016003643A (es)	2013-09-30	2016-12-20	Daiichi Sankyo Co Ltd	Anticuerpo anti-lps o11.
WO2015150326A1 (en) *	2014-03-31	2015-10-08	Universiteit Gent	A method of treating bone disease
KR20180021723A (ko)	2015-06-29	2018-03-05	다이이찌 산쿄 가부시키가이샤	항체-약물 콘주게이트의 선택적 제조 방법
EP4512827A3 (en) *	2015-11-10	2025-04-30	Yale University	Compositions and methods for treating autoimmune diseases and cancers
EP4360714A3 (en) *	2016-09-21	2024-07-24	Nextcure, Inc.	Antibodies for siglec-15 and methods of use thereof
KR20240035625A (ko)	2016-09-21	2024-03-15	넥스트큐어 인코포레이티드	Siglec-15를 위한 항체 및 이의 사용 방법
AU2018218753A1 (en)	2017-02-07	2019-09-26	Daiichi Sankyo Company, Limited	Anti-GPRC5D antibody and molecule containing same
TWI782000B (zh)	2017-03-30	2022-11-01	日商第一三共股份有限公司	抗ｇｐｒ２０抗體、其製造方法及其應用
CN110913905A (zh)	2017-06-30	2020-03-24	国立大学法人北海道大学	不产生生长障碍的小儿骨质疏松症治疗药
WO2019022187A1 (ja)	2017-07-27	2019-01-31	第一三共株式会社	抗ｃｄ１４７抗体
TW202521585A (zh)	2018-05-31	2025-06-01	日商第一三共股份有限公司	抗人類tlr7抗體、其用途及醫藥組成物
EP3831853A4 (en)	2018-07-27	2022-06-01	Daiichi Sankyo Company, Limited	ANTIBODY-DRUG CONJUGATE PROTEIN-RECOGNIZING DRUG UNIT
KR102655828B1 (ko)	2018-08-16	2024-04-08	이엠디 밀리포어 코포레이션	폐쇄된 바이오프로세싱 장치
CN111378043B (zh) *	2020-02-19	2021-02-09	南京医科大学	一种具有中和作用的人鼠嵌合抗Siglec-15全分子IgG及其制备方法和应用
CN112159475B (zh) *	2020-10-10	2021-04-30	南京凯地生物科技有限公司	Siglec-15单克隆抗体及其应用
CN112625132B (zh) *	2021-01-15	2022-08-02	沈阳荣欣生物制药科技有限公司	纳米抗体及其编码基因、表达载体、宿主细胞和应用
CN114957468A (zh) *	2021-02-25	2022-08-30	石药集团巨石生物制药有限公司	一种抗Siglec15抗体及其用途
CN112979761B (zh) *	2021-03-19	2021-12-10	江苏元本生物科技有限公司	一种靶向Siglec-15的噬菌体多肽
CN112961214B (zh) *	2021-03-19	2022-08-02	江苏元本生物科技有限公司	一种靶向Siglec-15的噬菌体多肽
CN113577283A (zh) *	2021-07-19	2021-11-02	河北医科大学第三医院	Siglec-15抑制剂在制备防治骨巨细胞瘤药物中的应用
CN114807052A (zh) *	2022-06-07	2022-07-29	江苏亲科生物研究中心有限公司	Siglec15单克隆抗体及其制备方法和用途
WO2024022008A1 (zh) *	2022-07-26	2024-02-01	北京东方百泰生物科技股份有限公司	一种抗Siglec-15单克隆抗体、其抗原结合片段及其应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5260203A (en)	1986-09-02	1993-11-09	Enzon, Inc.	Single polypeptide chain binding molecules
US5091513A (en)	1987-05-21	1992-02-25	Creative Biomolecules, Inc.	Biosynthetic antibody binding sites
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5116828A (en) *	1989-10-26	1992-05-26	Nippon Zoki Pharmaceutical Co., Ltd.	Pharmaceutical composition for treatment of osteoporosis
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
CA2109602C (en)	1990-07-10	2002-10-01	Gregory P. Winter	Methods for producing members of specific binding pairs
EP0605522B1 (en)	1991-09-23	1999-06-23	Medical Research Council	Methods for the production of humanized antibodies
ES2341666T3 (es)	1991-12-02	2010-06-24	Medimmune Limited	Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5660827A (en) *	1992-03-05	1997-08-26	Board Of Regents, The University Of Texas System	Antibodies that bind to endoglin
DE69333823T2 (de)	1992-03-24	2006-05-04	Cambridge Antibody Technology Ltd., Melbourn	Verfahren zur herstellung von gliedern von spezifischen bindungspaaren
GB9313509D0 (en)	1993-06-30	1993-08-11	Medical Res Council	Chemisynthetic libraries
EP0731842A1 (en)	1993-12-03	1996-09-18	Medical Research Council	Recombinant binding proteins and peptides
IL117175A (en) *	1995-02-20	2005-11-20	Sankyo Co	Osteoclastogenesis inhibitory factor protein
DE19653646A1 (de)	1996-12-20	1998-06-25	Hoechst Ag	Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
DK0911342T4 (da)	1997-04-15	2013-07-29	Daiichi Sankyo Co Ltd	Nyt protein og fremgangsmåde til fremstilling deraf
KR20010034840A (ko)	1998-05-08	2001-04-25	나카노 카츠히코	신규한 스피로화합물 또는 그 염, 이들을 함유하는자기면역질환예방 치료제 및 ａｐ-1 저해제
US20030036631A1 (en) *	2000-07-21	2003-02-20	Malinda Longphre	Novel siglecs and uses thereof
US7608704B2 (en) *	2000-11-08	2009-10-27	Incyte Corporation	Secreted proteins
CA2428140A1 (en)	2000-11-08	2002-05-16	Incyte Genomics, Inc.	Secreted proteins
WO2002064771A1 (fr)	2001-02-15	2002-08-22	Mochida Pharmaceutical Co., Ltd.	Nouvelle molecule d'adhesion cellulaire specifique de leucocyte active
PH12012502439A1 (en)	2001-06-26	2013-06-17	Amgen Inc	Antibodies to opgl
AU2002364699A1 (en)	2001-11-13	2003-06-17	Incyte Genomics, Inc.	Receptors and membrane-associated proteins
US7193069B2 (en)	2002-03-22	2007-03-20	Research Association For Biotechnology	Full-length cDNA
JP4761710B2 (ja) *	2002-04-05	2011-08-31	アムジェンインコーポレイテッド	選択的ｏｐｇｌ経路インヒビターとしてのヒト抗ｏｐｇｌ中和抗体
BRPI0406678A (pt)	2003-01-07	2005-12-20	Symphogen As	Método para produzir proteìnas policlonais recombinantes
TWI359026B (en) *	2004-02-12	2012-03-01	Sankyo Co	Pharmaceutical composition for the osteoclast rela
JP4633491B2 (ja) *	2004-02-12	2011-02-16	第一三共株式会社	破骨細胞関連タンパク質を標的とした抗体
US7405037B2 (en)	2004-05-07	2008-07-29	Lonza Walkersville, Inc.	Methods and tools for detecting collagen degradation
CN101035807A (zh) *	2004-06-09	2007-09-12	泰勒公司	Siglec－6相关疾病的诊断和治疗
JP4604184B2 (ja) *	2005-07-12	2010-12-22	独立行政法人産業技術総合研究所	新規糖鎖認識蛋白質及びその遺伝子
GB0521991D0 (en) *	2005-10-28	2005-12-07	Univ Dundee	Siglec-9 binding agents
US8168181B2 (en)	2006-02-13	2012-05-01	Alethia Biotherapeutics, Inc.	Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
CA2822302A1 (en) *	2006-02-13	2007-08-23	Alethia Biotherapeutics Inc.	Methods of impairing osteoclast differentiation
RU2475499C2 (ru)	2007-10-11	2013-02-20	Дайити Санкио Компани, Лимитед	Антитело, направленное на белок siglec-15, связанный с остеокластами
NZ605450A (en) *	2009-04-09	2014-07-25	Daiichi Sankyo Co Ltd	Anti-siglec-15 antibody
EP2585349B1 (fr)	2010-06-23	2014-12-31	Creissels Technologies	Installation a cables aeriens et a vehicule asservi, sans suspente
US9114131B2 (en)	2010-10-05	2015-08-25	Daiichi Sankyo Company, Limited	Antibody targeting osteoclast-related protein Siglec-15
US20150125470A1 (en)	2012-03-30	2015-05-07	Daiichi Sankyo Company, Limited	Novel anti-siglec-15 antibody
RU2014143798A (ru)	2012-03-30	2016-05-27	Дайити Санкио Компани, Лимитед	Антитело к сиглек-15 с модифицированной cdr

2008
- 2008-10-08 RU RU2010106639/10A patent/RU2475499C2/ru active
- 2008-10-08 ES ES08838427.6T patent/ES2540733T3/es active Active
- 2008-10-08 PT PT88384276T patent/PT2206727E/pt unknown
- 2008-10-08 CN CN200880110441.XA patent/CN101896501B/zh not_active Expired - Fee Related
- 2008-10-08 CA CA2875310A patent/CA2875310A1/en not_active Abandoned
- 2008-10-08 SI SI200831433T patent/SI2206727T1/sl unknown
- 2008-10-08 SG SG2013006002A patent/SG187523A1/en unknown
- 2008-10-08 DK DK08838427.6T patent/DK2206727T3/en active
- 2008-10-08 EP EP15161779.2A patent/EP2907826B1/en active Active
- 2008-10-08 CN CN201710983720.8A patent/CN108130327A/zh active Pending
- 2008-10-08 WO PCT/JP2008/068287 patent/WO2009048072A1/ja not_active Ceased
- 2008-10-08 BR BRPI0818437A patent/BRPI0818437B8/pt not_active IP Right Cessation
- 2008-10-08 NZ NZ583397A patent/NZ583397A/en not_active IP Right Cessation
- 2008-10-08 MX MX2010003884A patent/MX2010003884A/es active IP Right Grant
- 2008-10-08 JP JP2009537006A patent/JPWO2009048072A1/ja not_active Withdrawn
- 2008-10-08 AU AU2008311698A patent/AU2008311698C1/en not_active Ceased
- 2008-10-08 EP EP08838427.6A patent/EP2206727B1/en active Active
- 2008-10-08 KR KR1020157004726A patent/KR101577935B1/ko not_active Expired - Fee Related
- 2008-10-08 HR HRP20150485TT patent/HRP20150485T1/hr unknown
- 2008-10-08 US US12/677,621 patent/US8546540B2/en active Active
- 2008-10-08 HU HUE08838427A patent/HUE025262T2/en unknown
- 2008-10-08 KR KR1020107005095A patent/KR101534884B1/ko not_active Expired - Fee Related
- 2008-10-08 ES ES15161779T patent/ES2677246T3/es active Active
- 2008-10-08 PL PL08838427T patent/PL2206727T3/pl unknown
- 2008-10-08 SG SG10201605897RA patent/SG10201605897RA/en unknown
- 2008-10-08 CA CA2698326A patent/CA2698326C/en active Active
- 2008-10-09 TW TW097138812A patent/TWI511740B/zh not_active IP Right Cessation
2010
- 2010-02-24 ZA ZA201001339A patent/ZA201001339B/xx unknown
- 2010-03-18 IL IL204607A patent/IL204607A/en active IP Right Grant
2012
- 2012-02-27 AU AU2012201263A patent/AU2012201263B9/en not_active Ceased
- 2012-04-27 US US13/457,967 patent/US9090692B2/en active Active
- 2012-05-25 US US13/481,016 patent/US10723800B2/en active Active
- 2012-07-30 RU RU2012132678/10A patent/RU2012132678A/ru not_active Application Discontinuation
2013
- 2013-04-05 JP JP2013080007A patent/JP5845207B2/ja active Active
2014
- 2014-08-12 IL IL234078A patent/IL234078B/en active IP Right Grant
2015
- 2015-06-30 CY CY20151100562T patent/CY1116432T1/el unknown
- 2015-08-14 US US14/826,515 patent/US9815899B2/en active Active
- 2015-11-20 JP JP2015227272A patent/JP6116652B2/ja active Active
2017
- 2017-03-21 JP JP2017053853A patent/JP6440759B2/ja active Active
- 2017-10-11 US US15/729,947 patent/US10308715B2/en active Active

Also Published As

Publication number	Publication date
JP2016074694A (ja)	2016-05-12
IL234078A0 (en)	2014-09-30
US10723800B2 (en)	2020-07-28
IL204607A0 (en)	2010-11-30
JP5845207B2 (ja)	2016-01-20
KR20150031489A (ko)	2015-03-24
EP2206727A4 (en)	2011-03-02
AU2012201263A1 (en)	2012-03-22
IL234078B (en)	2018-08-30
US20180037656A1 (en)	2018-02-08
MX2010003884A (es)	2010-04-30
CN108130327A (zh)	2018-06-08
SG187523A1 (en)	2013-02-28
KR101534884B1 (ko)	2015-07-08
ES2540733T3 (es)	2015-07-13
ZA201001339B (en)	2010-10-27
CY1116432T1 (el)	2017-02-08
RU2010106639A (ru)	2011-08-27
HK1209135A1 (en)	2016-03-24
PL2206727T3 (pl)	2015-08-31
TW200927168A (en)	2009-07-01
HUE025262T2 (en)	2016-02-29
CA2698326C (en)	2015-03-17
EP2907826A1 (en)	2015-08-19
JP6116652B2 (ja)	2017-04-19
CN101896501A (zh)	2010-11-24
US10308715B2 (en)	2019-06-04
US20150344578A1 (en)	2015-12-03
US20120251485A1 (en)	2012-10-04
TWI511740B (zh)	2015-12-11
CA2698326A1 (en)	2009-04-16
EP2206727B1 (en)	2015-04-01
SG10201605897RA (en)	2016-09-29
ES2677246T3 (es)	2018-07-31
KR20100065153A (ko)	2010-06-15
JP6440759B2 (ja)	2018-12-19
BRPI0818437B8 (pt)	2021-05-25
HK1145847A1 (en)	2011-05-06
EP2206727A1 (en)	2010-07-14
AU2008311698C1 (en)	2014-03-06
US9815899B2 (en)	2017-11-14
WO2009048072A1 (ja)	2009-04-16
AU2012201263B9 (en)	2017-06-01
US8546540B2 (en)	2013-10-01
JP2017155044A (ja)	2017-09-07
AU2012201263B2 (en)	2017-04-20
CA2875310A1 (en)	2009-04-16
AU2008311698B2 (en)	2011-12-01
BRPI0818437B1 (pt)	2021-03-30
SI2206727T1 (sl)	2015-06-30
JP2013144708A (ja)	2013-07-25
US9090692B2 (en)	2015-07-28
HRP20150485T1 (xx)	2015-06-19
US20120230988A1 (en)	2012-09-13
DK2206727T3 (en)	2015-07-06
IL204607A (en)	2016-03-31
EP2907826B1 (en)	2018-05-30
NZ583397A (en)	2012-03-30
JPWO2009048072A1 (ja)	2011-02-17
CN101896501B (zh)	2017-11-07
US20100209428A1 (en)	2010-08-19
BRPI0818437A8 (pt)	2019-01-15
RU2012132678A (ru)	2014-02-10
KR101577935B1 (ko)	2015-12-16
RU2475499C2 (ru)	2013-02-20
PT2206727E (pt)	2015-08-05
AU2008311698A1 (en)	2009-04-16

Publication	Publication Date	Title
BRPI0818437A2 (pt)	2015-05-12	Anticorpo ou fragmento funcional do anticorpo, composição farmacêutica, uso de pelo menosum dos anticorpos ou fragmentos funcionais dos anticorpos, e, hibridoma
HUS2300026I1 (hu)	2023-09-28	Anti-CTLA-4 ellenanyag készítmények
BRPI0919377A2 (pt)	2016-09-27	anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
BRPI1005322A2 (pt)	2019-09-24	anticorpo, composição farmacêutica e uso de pelo menos um anticorpo
IL194550A (en)	2015-06-30	Isolated antibodies or their fragments that bind to human protein tyrosine phosphate in a cell, their pharmaceutical preparations and their use
CL2007000478A1 (es)	2008-03-14	Anticuerpo humano o humanizado o fragmento funcional del mismo especifico para linfopoyetina estromal timica, tslp; polinucleotido que lo codifica; celula huesped que lo comprende; composicion farmaceutica que comprende al anticuerpo; y metodo para t
BR112012022210A2 (pt)	2017-09-05	anticorpo isolado ou seu fragmento imunorreativo, molécula de ácido nucleico, composição farmacêutica, e, uso do anticorpo isolado
IL219653A0 (en)	2012-06-28	Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
BRPI0821447A2 (pt)	2015-06-16	Anticorpo de alvejamento engenheirado, composição farmacêutica, hibridoma, ensaio com base em anticorpo, polipeptídeo isolado, e, método para ligação homogênea
EA200970210A1 (ru)	2009-08-28	Prlr-специфическое антитело и его применения
BRPI1006134A2 (pt)	2016-02-23	anticorpo ou um fragmento funcional do anticorpo, composição farmacêutica, uso de um anticorpo ou um fragmento funcional do mesmo, polinucleotídeo, vetor, e, célula hospedeira transformada.
HUE037642T2 (hu)	2018-09-28	Humán cd134 (ox40) humán monoklonális antitest és eljárások annak elõállítására és alkalmazására
UA94628C2 (ru)	2011-05-25	Гуманизированное моноклональное антитело, которое связывается с steap-1, и его применение
WO2006099698A3 (en)	2006-11-30	Novel anti-plgf antibody
HUE048404T2 (hu)	2020-07-28	Claudin-18 elleni monoklonális antitestek rák kezelésére
CY2018018I2 (el)	2018-12-12	Θεραπεια του οικογενους μεσογειακου πυρετου με αντι-il-1b αντισωματα
NO20083891L (no)	2008-12-03	Anti-5T4 antistoffer og anvendelser derav
AR057807A1 (es)	2007-12-19	Formulaciones de anticuerpo anti-cd3
BRPI0818780A2 (pt)	2015-04-22	Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos
BRPI0510170B8 (pt)	2021-05-25	composto, composição farmacêutica para o tratamento de doenças mediadas pelo receptor muscarínico de acetilcolina e uso do composto
IL219268A (en)	2015-02-26	Anti-b79cd antibody, immunosuppressant and pharmacological agent that includes and uses it
WO2008134724A3 (en)	2009-02-12	Methods for administering anti-il-5 antibodies
WO2008140493A3 (en)	2009-05-14	Anti-egfr family antibodies, bispecific anti-egfr family antibodies and methods of use thereof
BRPI0811635A2 (pt)	2014-11-11	Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos
CY1113087T1 (el)	2016-04-13	Ανθρωπινα αντισωματα εναντιον δελτα-παρομοιου προσδεματος 4

Legal Events

Date	Code	Title	Description
2019-01-22	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-04-16	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2019-10-01	B15K	Others concerning applications: alteration of classification	Free format text: A CLASSIFICACAO ANTERIOR ERA: F04B 39/00 Ipc: C07K 16/28 (1995.01), C07K 14/42 (1995.01), A61K 3
2019-10-22	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]	Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.
2020-10-20	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2021-03-09	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2021-03-30	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 30/03/2021, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/10/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF
2024-07-30	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 16A ANUIDADE.
2024-11-19	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2795 DE 30-07-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.